Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.65 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.61 |
| ▸ | BRD4 | O60885 | 12/20 | 0.58 |
| ▸ | TAF1 | P21675 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748892 | 0.84 | CECR2 (0.73) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL17748943 | 0.79 | CECR2 (1.00) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL17748893 | 0.77 | BRD9 (0.71) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL17748929 | 0.77 | CECR2 (1.00) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL17756347 | 0.77 | BRD9 (1.00) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL24866050 | 0.74 | BRD4 (0.76) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL17748888 | 0.74 | BRD4 (1.00) | CECR2BRD9BRD4TAF1 | |
| SCHEMBL4790337 | 0.73 | CIT (0.65) | — | |
| SCHEMBL17286122 | 0.72 | DYRK1A (0.55) | — | |
| SCHEMBL17748906 | 0.72 | CECR2 (1.00) | CECR2BRD9BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | claimed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3250571-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3218375-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3218374-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077378-A1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016077380-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | CECR2 246/4885BRD9 12/4885BRD4 1/4885 |
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | CECR2 1389/4885BRD9 1516/4885BRD4 699/4885 |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | CECR2 246/4885BRD9 12/4885BRD4 1/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | CECR2 246/4885BRD9 12/4885BRD4 1/4885 |
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CECR2 184/4885BRD9 16/4885BRD4 1/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CECR2 184/4885BRD9 16/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.